STOCK TITAN

Twist Bioscience Corporation (TWST) Stock News, Oct-Nov 2020

TWST NASDAQ

Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.

Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.

Rhea-AI Summary

Twist Bioscience (TWST), along with Illumina (ILMN), Western Digital (WDC), and Microsoft, has formed a strategic alliance to advance DNA data storage. This coalition aims to create an industry roadmap for interoperability and commercial solutions as demand for archival storage surges due to data growth. DNA's durability and density—storing massive amounts of data in minimal space—position it as a viable alternative to traditional storage. The alliance anticipates that by 2024, 30% of digital businesses will initiate DNA storage trials, addressing the urgent need for long-term solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the fiscal 2020 fourth quarter and full year on November 23, 2020, before market opening. A conference call at 8:00 a.m. ET will discuss these results and provide a business update. Investors can access the financial release via the Investor Relations section on the company's website. Twist Bioscience focuses on synthetic DNA manufacturing using a proprietary silicon platform, catering to various industries including healthcare and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
conferences earnings
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) and Neogene Therapeutics have announced a strategic partnership to develop personalized T cell therapies for cancer. The collaboration combines Neogene's expertise in identifying tumor neo-antigens with Twist's synthetic DNA synthesis platform. Twist will create a specialized T cell receptor (TCR) library for Neogene, focusing on two cancer targets. The partnership aims to expedite the development of innovative cancer treatments and includes technology access fees, milestones, and royalties tied to preclinical and clinical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
partnership

FAQ

What is the current stock price of Twist Bioscience (TWST)?

Twist Bioscience (TWST) last closed at $116.35.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately $7.9B.